Tibolone: a compound with tissue specific inhibitory effects on sulfatase

Area of Science:

• Endocrinology
• Pharmacology
• Cell Biology

Background:

• Tibolone is a synthetic steroid used for hormone replacement therapy.
• Sulfatases are enzymes that remove sulfate groups, influencing hormone activity.
• Tissue-specific effects of drugs are crucial for therapeutic efficacy and safety.

Purpose of the Study:

• To investigate the differential regulation of sulfatase activity by tibolone and its metabolites in human bone, endometrium, and breast cells.
• To determine if selective sulfatase inhibition by tibolone contributes to its tissue-specific actions.

Main Methods:

• Human cell lines representing bone (MG 63, HOS TE-85), endometrium (HEC-1A), and breast (T-47D clones) were used.
• Sulfatase activity was measured in the presence of tibolone, its metabolites (3 alpha- and 3 beta-hydroxy, sulfated forms, Delta(4)-isomer), and the specific inhibitor EMATE.
• Intracellular conversion of 3 alpha-sulfated tibolone was assessed.

Main Results:

• Tibolone and its metabolites strongly inhibited sulfatase activity in breast cells (70-90%) and intermediately in endometrial cells (8-43%).
• No significant inhibition of sulfatase was observed in osteoblast-like bone cells.
• The specific sulfatase inhibitor EMATE inhibited activity across all cell types.
• 3 alpha-sulfated tibolone was intracellularly converted to 3 alpha-hydroxy-tibolone by sulfatase in all tested cell lines.

Conclusions:

• Tibolone exhibits tissue-specific inhibition of sulfatase activity, primarily affecting breast and endometrial cells.
• This selective inhibition pattern suggests a potential protective role against mammary carcinomas.
• Tibolone may retain beneficial estrogenic effects on bone due to lack of sulfatase inhibition in bone cells.